Persistent parvovirus-associated chronic fatigue treated with high dose intravenous immunoglobulin

Pediatric Infectious Disease Journal

Volumn 24, Issue 3, 2005, Pages 272-274

  McGhee, Sean A ^a   Kaska, Benjamin ^c   Liebhaber, Myron ^b   Stiehm, E Richard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Santa Barbara Medical Foundation   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic fatigue syndrome; Intravenous immunoglobulin; Parvovirus B19

Indexed keywords

IMMUNOGLOBULIN; PREDNISOLONE;

ADOLESCENT; ARTICLE; CASE REPORT; CHRONIC FATIGUE SYNDROME; ERYTHEMA INFECTIOSUM; FEVER; HUMAN; IMMUNE DEFICIENCY; IMMUNE STATUS; MALE; PARVOVIRUS; PRIORITY JOURNAL; RASH; VIREMIA;

ADOLESCENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE SYNDROME, CHRONIC; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; PARVOVIRIDAE INFECTIONS; PARVOVIRUS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 14944382883     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000155194.66797.20     Document Type: Article

References (22)

1. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990;113:926-933.
2. Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS. Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet. 1988;2:1159-1162.
3. Seyama K, Kobayashi R, Hasle H, et al. Parvovirus B19-induced anemia as the presenting manifestation of X-linked hyper-IgM syndrome. J Infect Dis. 1998;178:318-324.
4. Kerr JR, Barah F, Mattey DL, Laing I, Hopkins SJ, Hutchinson IV, Tyrrell DA. Circulating tumour necrosis factor-α and interferon-γ are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol. 2001;82:3011-3019.
5. Jacobson SK, Daly JS, Thorne GM, McIntosh K. Chronic parvovirus B19 infection resulting in chronic fatigue syndrome: case history and review. Clin Infect Dis. 1997;24:1048-1051.
6. Gallineila G, Zerbini M, Musiani M, Venturoli S, Gentilomi G, Manaresi E. Quantitation of parvovirus B19 DNA sequences by competitive PCR: differential hybridization of the amplicons and immunoenzymatic detection on microplate. Mol Cell Probes. 1997;11:127-133.
7. Kerr JR, Cunniffe VS, Kelleher P, Bernstein RM, Bruce IN. Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. Clin Infect Dis. 2003;36:e100-e106.
8. Anderson MJ, Lewis E, Kid IM, et al. An outbreak of erythema infectiosum associated with human parvovirus infection. J Hyg. 1984;93:85-93.
9. Moreux N, Ranchin B, Calvet A, Bellon G, Levrey-Hadden H. Chronic parvovirus B19 infection in a pediatric lung transplanted patient. Transplantation. 2002;73:565-568.
10. Sinclair JP, Croxson MC, Thomas SM, Teague LR, Mauger DC. Chronic parvovirus B19 meningitis in a child with acute lymphocytic leukemia. Pediatr Infect Dis J. 1999;18:395-396.
11. Diaz F, Collazos J. Hepatic dysfunction due to parvovirus B19 infection. J Infect Chemother. 2000;6:63-64.
12. Cassinotti P, Burtonboy G, Fopp M, Siegl G. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol. 1997;53:229-232.
13. LaMonte AC, Paul ME, Read JS, et al. Persistent parvovirus B19 infection without the development of chronic anemia in HIV-infected and -uninfected children: the Women and Infants Transmission Study. J Infect Dis. 2004;189:847-851.
14. Soderlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet. 1997;349:1063-1065.
15. Kerr JR, Bracewell J, Laing I, et al. Chronic fatigue syndrome and arthralgia following parvovirus B19 infection. J Rheumatol. 2002;29:595-602.
16. Young NS, Brown KE. Mechanisms of disease: parvovirus B19. N Engl J Med. 2004;350:586-597.
17. Arribas JR, Pena JM, Echevarria JE. Parvovirus B19-related anemia in an HIV-infected patient: rapid control after production of neutralizing antibodies during highly active antiretroviral therapy. Ann Intern Med. 2000;132:1011.
18. Liefeldt L, Buhl M, Schweickert B, et al. Eradication of parvovirus B19 infection after renal transplantation requires reduction of immunosuppression and high-dose immunoglobulin therapy. Nephrol Dial Transplant. 2002;17:1840-1842.
19. Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am J Med. 1990;89:561-568.
20. Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, et al. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. Am J Med. 1997;103:38-43.
21. Ilaria RLJ, Komaroff AL, Fagioli LR, Moloney WC, True CA, Naides SJ. Absence of parvovirus B19 infection in chronic fatigue syndrome. Arthritis Rheum. 1995;38:638-664.
22. Chia JK, Chia A. Diverse etiologies for chronic fatigue syndrome. Clin Infect Dis. 2003;36:671-672.